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Expression of EBNA-1 protein is required for the establishment and maintenance of the Epstein-Barr virus
(EBV) genome during latent infection. During type I latency, the BamHI Q promoter (Qp) gives rise to EBNA-1
expression. The dominant regulatory mechanism for Qp appears to be mediated through the Q locus, located
immediately downstream of the transcription start site. Binding of EBNA-1 to the Q locus represses Qp con-
stitutive activity, and repression has been reported to be overcome by an E2F family member that binds to the
Q locus and displaces EBNA-1 (N. S. Sung, J. Wilson, M. Davenport, N. D. Sista, and J. S. Pagano, Mol. Cell.
Biol. 14:7144–7152, 1994). These data suggest that the final outcome of Qp activity is reciprocally controlled
by EBNA-1 and E2F. Since E2F activity is cell cycle regulated, Qp activity and EBNA-1 expression are predicted
to be regulated in a cell cycle-dependent manner. Proliferation of the type I latently infected cell line, Akata,
was synchronized with the use of the G2/M blocking agent nocodazole. From 65 to 75% of cells could be made
to peak in S phase without evidence of viral reactivation. Following release from G2/M block, EBNA-1 mRNA
levels declined as the synchronized cells entered the G1 phase of the cell cycle. As cells proceeded into S phase,
EBNA-1 mRNA levels increased parallel to the peak in cell numbers in S phase. However, EBNA-1 protein lev-
els showed no detectable change during the cell cycle, most likely due to the protein’s long half-life as estimated
by inhibition of protein synthesis by cycloheximide. Finally, in Qp luciferase reporter assays, the activity of Qp
was shown to be regulated by cell cycle and to be dependent on the E2F sites within the Q locus. These findings
demonstrate that transcriptional activity of Qp is cell cycle regulated and indicated that E2F serves as the
stimulus for this regulation.
Following primary cytolytic infection of epithelial cells in the
oropharynx, Epstein-Barr virus (EBV) infects B lymphocytes,
in which it establishes latent infection. EBV can establish three
types of latency (I, II, and III) associated with malignancy, each
of which is characterized by the differential expression of a
group of latency proteins. One of these proteins, Epstein-Barr
nuclear antigen 1 (EBNA-1), is expressed during all three
types of latent infection and is the only protein absolutely re-
quired for maintenance of latency (reviewed in reference 24).
During latency, the EBV genome is maintained as an episome
which requires EBNA-1 for replication (39, 69). EBNA-1’s
function is to act in trans by binding to 24 sites clustered within
the viral genome, called the origin of latent replication (oriP),
and regulate episomal replication (4, 23, 46).
Although EBNA-1 expression is common to the three types
of latency, the promoter used for its expression differs. During
type III latency, EBNA-1 is expressed from the BamHI C and
W promoters (Cp/Wp) (reviewed in reference 24). In type I
and II latency, Cp/Wp are inactive, and EBNA-1 is expressed
from the BamHI Q promoter (Qp) (38, 53, 63). In addition to
latent expression, EBNA-1 mRNA is apparently transcribed
during the viral lytic cycle from a fourth promoter called the
BamHI F promoter (Fp) (25, 38, 52). Fp was originally misi-
dentified as the promoter used for EBNA-1 expression during
type I latency, but this conclusion was based on experiments in
which a portion of the cells were undergoing spontaneous
cytolytic replication (49, 54).
The control of Qp and EBNA-1 expression during type I
latency has received intensive study. Qp appears to be con-
trolled by two important regulatory elements. The first is an
interferon-stimulated response element (ISRE) which lies up-
stream of the Qp transcriptional start site and is bound by
members of the interferon regulatory factor (IRF) family (37,
51, 71). These factors include positive and negative regulatory
proteins which appear to be important for the constitutive
activity of Qp. Immediately downstream of the start site lie
two binding sites for the EBNA-1 protein (4, 46). These sites,
called the Q locus, are the only other EBNA-1 binding sites
outside of oriP. They are lower-affinity binding sites relative to
oriP, and binding of EBNA-1 to these sites represses Qp ac-
tivity (4, 23, 50, 56, 57, 63). Furthermore, this repression ap-
pears to override the effects of positive regulatory elements
that lie upstream of the Qp start site.
These data raise an important question: how is Qp activated
during type I latency when EBNA-1 is present and able to re-
press Qp? We have reported that a member of the E2F family
of cellular transcription factors upregulates Qp in the presence
of EBNA-1 (56). Additionally, E2F-1 binds in vitro to se-
quences within the Q locus that partially overlap the two
EBNA-1 binding sites. These data suggest that EBNA-1 and
E2F control the final outcome of Qp activity. When EBNA-1 is
bound to the Q locus, Qp is repressed. E2F can overcome re-
pression by binding to the Q locus, displacing or competing
with EBNA-1 binding and thereby activating Qp.
E2F constitutes a family of cellular transcription factors
which regulate cellular promoters for proteins important in cell
cycle progression. E2F transcriptional activity is cell cycle reg-
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ulated (reviewed in references 2, 20, 32, and 34). In early G1,
E2F exists in a complex with the underphosphorylated form of
the retinoblastoma (Rb) tumor suppressor protein. As G1 pro-
ceeds, Rb becomes hyperphosphorylated, releasing E2F which
is now able to transactivate its responsive genes (reviewed in
references 2, 11, 20, 32, 34, and 65). Many of these genes, in-
cluding those encoding DNA polymerase a, ribonucleotide
reductase (RR), cyclins A and E, and HsOrc1, are responsible
for synthesis of cellular DNA and/or progression of the cell
cycle (12, 17, 41, 42, 48, 55). Presumably, one or more of these
genes is involved in replication of EBV episomes which are
replicated by host enzymes during latency (67, 69).
Since E2F appears to activate Qp, we hypothesized that Qp
activity and expression of EBNA-1 are cell cycle regulated (56).
To test this prediction, we first established a system to synchro-
nize growth of a type I latently infected cell line. EBNA-1
message and protein levels were then measured following syn-
chronization to determine if their expression is cell cycle reg-
ulated. We show that expression of EBNA-1 mRNA is clearly
linked to cell cycle but that the level of EBNA-1 protein does
not vary detectably, perhaps due to its long half-life. We also
demonstrate that mutation of the E2F sites in Qp luciferase
reporter constructs abolished cell cycle regulation of the pro-
moter.
MATERIALS AND METHODS
Cell culture, synchronization, and fluorescence-activated cell sorting (FACS)
analysis. Akata (59), Raji (45), DG75 (5), X50-7 (66), and BL41 958 cells (19)
were maintained in RPMI 1640–10% fetal bovine serum (FBS)–penicillin-strep-
tomycin (pen-strep). Human embryonic lung fibroblasts (HELs; gift of S. Bach-
enheimer) and NIH 3T3 mouse fibroblasts were maintained in Dulbecco mod-
ified Eagle medium-high glucose (DMEM-H)–10% FBS–pen-strep.
Akata cells were synchronized in G2/M by treatment with nocodazole (0.04
mg/ml) for 14 h. Following block, cells were washed and replated with fresh
RPMI 1640–10% FBS–pen-strep; samples were taken every 3 h. For each time
point, 4 3 106 cells were fixed with 80% ethanol for FACS analysis. The remain-
ing cells were harvested, and either total RNA or protein lysates were prepared.
HELs were synchronized by serum starvation in DMEM-H–1% FBS–pen-
strep for 48 h and then replated in DMEM-H–10% FBS–pen-strep. At 0 and 18 h
following replating, 4 3 106 cells were fixed with 80% ethanol for FACS analysis,
and the remaining cells were harvested for protein lysates.
To determine DNA content and cell cycle status of each time point, 2 3 106
fixed cells were spun down, washed once with 13 phosphate-buffered saline
(PBS)–1% bovine serum albumin, and resuspended in 1.12% sodium citrate–
0.1% Triton X-100–2 mg of RNase A per ml–50 mg of propidium iodine per ml.
Data were acquired on a Becton Dickinson FACSStarPlus and analyzed by using
ModFit.
RNA preparation and EBNA-1 mRNA analysis. Total RNA was prepared
from time point samples and from control cell lines by using a Qiagen RNeasy
midi kit. For Northern analysis of EBNA-1 mRNA, 50-mg aliquots of total RNA
from synchronized Akata cells at each time point or controls were electropho-
resed on 1% agarose-formaldehyde gels and transferred to nitrocellulose (BA85;
Schleicher & Schuell). The nitrocellulose was cut in two, and EBNA-1 mRNA
expression was detected in the top half with a riboprobe made from the EBNA-
1 open reading frame (ORF) (minus Gly-Ala repeat). b-Actin expression was
determined by probing the bottom half with a random-primed labeled cDNA
probe (gift of W. E. Miller).
Use of CHX to estimate EBNA-1 protein half-life. Akata and X50-7 cells were
treated with cycloheximide (CHX; 50 mg/ml; Sigma) for 0, 1, 3, 6, 12, 24, 36, and
48 h. At each time point, cells were harvested, and protein lysates were prepared.
Protein lysates and immunoblotting for viral and cellular proteins. Total
cellular protein was prepared from control cell lines and time point samples.
Cells were washed once with 13 PBS and then resuspended in lysis buffer (50
mM Tris [pH 7.5], 150 mM NaCl, 5 mM EDTA, 0.5% Nonidet P-40, 5 mM
dithiothreitol, 10 mM NaF, 1 mM phenylmethylsulfonyl fluoride, Complete
[GIBCO-BRL]). After freezing and thawing three times, debris was spun down
at 4°C for 15 min, and the supernatant fluid was transferred to new tubes. Protein
concentration was determined by the Bradford protein assay.
For EBNA-1 Western analysis of synchronized cells, 75-mg aliquots of lysates
from each time point were separated by polyacrylamide gel electrophoresis
(PAGE) on a 8% sodium dodecyl sulfate (SDS)–polyacrylamide gel. For con-
trols, 75 and 25 mg of DG75 and Raji lysates, respectively, were run. For CHX
experiments, 100 mg of each CHX-treated Akata time point sample and 25 mg of
each CHX-treated X50-7 time point sample were used. Additionally, 100 mg of
DG75 and BL41 958 were run as controls. Proteins were transferred to either
Immobilon-P (Millipore) or NitroPlus (MSI), and EBNA-1 protein was detected
with monoclonal antibody (MAb) EBNA.OT1x (10) (gift of J. Middeldorp).
IRF-1 expression was determined by separating 25 mg of each CHX-treated
X50-7 time point sample and 100 mg of each CHX-treated Akata time point
sample on an SDS–8% polyacrylamide gel. As controls, 100 mg of DG75 and
BL41 958 lysates were run. Following transfer to NitroPlus (MSI), IRF-1 protein
was detected with polyclonal antibody (PAb) C-20 (Santa Cruz Biotechnology).
Expression of the EBV immediate-early protein Z was determined by sepa-
rating 50 mg of total protein from each time point on an SDS–12% polyacryl-
amide gel, transferring the material to Immobilon-P (Millipore), and detecting Z
protein with a BZLF-1 MAb.
For E2F-1 Western analysis, 50 mg of extract from each time point was
electrophoresed on an SDS–10% polyacrylamide gel. As controls, 150 mg of
serum-starved and released HEL extracts were run. Following transfer to Im-
mobilon-P (Millipore), E2F-1 protein was detected with MAb KH95 (Santa
Cruz).
For all Western analyses, proteins were visualized with either anti-mouse im-
munoglobulin (Ig)-horseradish peroxidase (Amersham) for MAbs EBNA.OT1x,
BZLF-1, and KH95 or anti-rabbit Ig-horseradish peroxidase for PAb C-20 (Am-
ersham) and enhanced chemiluminescence (Amersham).
Luciferase reporter constructs. pQLUC was cloned by digesting the previously
described pF2 chloramphenicol acetyltransferase (CAT) reporter construct (56)
with BamHI and XbaI. The resulting Qp sequence corresponding to 2173 to
1115 relative to the Qp transcription start site was blunt-end cloned into the
SmaI site of pGL-2 Basic (Promega). pQEcoCAT (56) was digested with BamHI
and XbaI to release Qp sequence 2173 to 1115, which was then blunt-end
cloned into the SmaI site of pGL-2 Basic. This construct, pQEcoLUC, is iden-
tical to pQLUC except for a 3-bp mutation in the downstream E2F site
(QpE2Fb) within the Q locus. pQ2LUC was constructed by digesting the con-
struct pQ2CAT, which contains Qp sequence 2173 to 15, with HindIII and
XbaI. The resulting Qp fragment was then blunt-end cloned into the SmaI site of
pGL-2 Basic. The pHsOrc1-Luc(21053) construct (41) was kindly provided by
J. Nevins.
Transfection and synchronization of NIH 3T3 mouse fibroblasts and lucif-
erase assays. The day before transfection, NIH 3T3 cells were plated in two
100-mm-diameter dishes per time point at 5 3 106 cells per dish with normal
growth medium (DMEM-H, 10% FBS, pen-strep). The following day each plate
was cotransfected with 5 mg of one luciferase reporter construct and 1 mg of
pCMV-b-gal (Clontech), using the SuperFect transfection reagent as specified by
the manufacturer (Qiagen). The cells were allowed to recover for 18 to 20 h and
were then placed in starvation medium (DMEM-H, 0.5% FBS, pen-strep) for
48 h. Following starvation, the cells were replated in growth medium and time
points were taken every 6 h. For each time point, two 100-mm-diameter dishes
were harvested, combined, and washed with 13 PBS. Half of the sample was
used for FACS analysis as described for the Akata synchronizations, and the
other half was used for protein extracts for b-galactosidase (b-Gal) and lucif-
erase assays.
Luciferase assays were performed as previously described (41). Each sample
was done in duplicate, and the amount of protein lysate used in each assay was
normalized by b-Gal activity.
RESULTS
Synchronization of type I latently infected Akata cells. To
determine whether the expression of EBNA-1 mRNA and
protein is coordinated with the cell cycle in type I latency,
growth of Akata cells was synchronized with nocodazole. The
Akata cell line was selected because it expresses the type I
latency phenotype in which EBNA-1 mRNA arises exclusively
from Qp (Fig. 1A and B). In our experience, this cell line is
also tightly latent with virtually no cells undergoing spontane-
ous lytic replication, as indicated by the absence of Z-protein
expression. Therefore, the EBNA-1 detected is not contami-
nated by lytic EBNA-1 expression thought to arise from Fp
(Fig. 1A and B) (25, 38, 52).
For all experiments described, cells were blocked with no-
codazole and then allowed to progress through the cell cycle by
replating in fresh drug-free medium (see Materials and Meth-
ods). Following drug removal, samples were taken every 3 h.
For each time point, DNA content and cell cycle status were
determined by staining with propidium iodide followed by
FACS analysis. The remaining cells were harvested to prepare
either total RNA or protein.
Nocodazole effectively synchronized Akata cells in the G2/M
phase of the cell cycle. Consistently, 65 to 85% of Akata cells
were blocked in G2/M, as determined by FACS analysis (Fig.
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2A and see Fig. 4A, 0 h). Following drug removal, the cells
proceeded through the cell cycle, with a majority of cells in G1
at 6 h and in S phase at 15 h (Fig. 2A and see Fig. 4A). Drug
treatment had no effect on cell viability (data not shown).
EBNA-1 mRNA is expressed in a cell cycle-dependent man-
ner during type I latency. To determine the expression of
EBNA-1 mRNA during the cell cycle, total RNA was prepared
from synchronized cells at each 3-h time point. Equivalent
amounts of RNA from each time point were electrophoresed
on formaldehyde gels, and EBNA-1 expression was deter-
mined by Northern analysis with a riboprobe of the EBNA-1
ORF (Fig. 2B). Northern analysis demonstrated that EBNA-1
mRNA expression varies during the cell cycle in Akata cells.
As cells enter G1, EBNA-1 expression decreases, with the least
expression at the G1 peak or 6 h following release from no-
codazole block (lane 6). Expression then increases and peaks,
with a corresponding increase and peak in the percentage of
S-phase cells at 15 h (lane 9). As controls for EBNA-1 expres-
sion, DG75, an EBV-negative Burkitt lymphoma line, lacks
EBNA-1 expression, as expected, in contrast to the EBV-pos-
itive Raji cell line, in which EBNA-1 mRNA is expressed. Raji
cells exhibit the type III latency program in which EBNA-1
expression arises from Cp/Wp (Fig. 1A). This EBNA-1 mRNA
has a size of approximately 3.5 kb, in contrast to Akata EBNA-
1 mRNA, which is approximately 2.5 kb, indicative of type I
latency (49).
These data demonstrate that expression of EBNA-1 tran-
scripts is regulated in a cell cycle-dependent manner during
type I latency. Because Qp expresses EBNA-1 mRNA during
type I latency, these data also suggest that Qp activity is cell
cycle regulated. The decrease in EBNA-1 mRNA expression
during G1 progression and its subsequent increase during S
phase suggest that Qp is inactive at the G1 peak and becomes
active as cells progress through S phase.
Nocadozole treatment does not induce the viral cytolytic
cycle. It is important to establish that synchronization of Akata
cells with nocodazole does not induce the viral cytolytic cycle.
Among the many agents that can induce latently EBV-infected
cell lines to enter the lytic cycle is the cell cycle-blocking agent
hydroxyurea, which induces Akata cells (data not shown).
EBNA-1 mRNA is thought to be expressed during the lytic
cycle from another promoter, Fp, which lies 193 bp upstream
of the latent Qp start site (Fig. 1B). Both latent and lytic
messages would have the same splice structure, with the Fp
message containing an additional 193 nucleotides at its 59 end
(Fig. 1A) (25, 38, 49, 52–54). Therefore, Northern analysis
does not permit the resolution of EBNA-1 messages arising
from Qp and Fp.
To determine if nocodazole induces the cytolytic cycle,
Akata cells were synchronized by nocodazole treatment as
described above. The cell cycle status at each time point is
shown in Fig. 4A. From each 6-h time point, equivalent
amounts of total cellular protein were separated by SDS-
PAGE, and expression of the EBV immediate-early protein Z
was determined (Fig. 3). Treatment of Akata cells with IgG
induces the viral lytic cycle and the expression of Z (lane 2)
(58). Figure 3 shows that Z is detected in neither the asynchro-
nous Akata cells nor at any time point following release from
FIG. 1. Promoters used for EBNA-1 expression. (A) The top line represents
part of the EBV genome, some of the BamHI restriction fragments, and the
promoters used for EBNA-1 expression (small arrows). The lower portion shows
the splice structure of the EBNA-1 mRNAs and their latency expression pat-
terns. Black rectangles represent exons, and the hatched rectangles designate the
EBNA-1 ORF. (B) Structure of Qp. The large and small arrows designate the Qp
(11) and Fp (2193) start sites, respectively. EBNA-1 binding sites are repre-
sented as black ovals (111 to 154); hatched rectangles represent the E2F-1
DNase I footprints (11 to 114 and 124 to 143; QpE2Fa and QpE2Fb, respec-
tively) (56); the ISRE is depicted as the open rectangle (218 to 25) (37, 51, 71).
(C) Comparison of the E2F sites from the B-myb (6), cyclin A (55), and cdc2 (61)
promoters with the Qp E2F sites, QpE2Fa and QpE2Fb (56). The box indicates
the core element identified in the B-myb and cdc2 E2F sites. The italicized
nucleotides show the matches between B-myb and QpE2Fb. The underlined se-
quence in QpE2Fa and QpE2Fb indicates the mutations of Nonkwelo et al. (36).
FIG. 2. Expression of EBNA-1 mRNA is cell cycle regulated. (A) Following
release from nocodazole block, cells from each 3-h time point were stained with
propidium iodide and analyzed by FACS to determine cell cycle status. (B) Ex-
pression of EBNA-1 and b-actin was analyzed by Northern hybridization using
50 mg of total Akata RNA from each time point (lanes 4 to 12), asynchronous Akata
cells (lane 3), Raji cells (lane 2), and DG75 cells (lane 1). The top panel dem-
onstrates EBNA-1 mRNA expression. Arrows mark EBNA-1 mRNA initiating
from Cp/Wp and Qp. The lower panel shows b-actin expression (marked with an
arrow). This is a representative result from four separate time course experiments.
FIG. 3. Treatment of Akata cells with nocodazole does not induce the viral
lytic cycle. Expression of the immediate-early protein Z was determined by West-
ern blotting as a marker for lytic induction. Fifty micrograms of total cellular
protein was used for each time point following release from nocodazole block
(lanes 4 to 8). Controls include 50 mg of total protein from uninduced Akata
(lane 1), induced Akata (treated for 24 h with IgG; lane 2), and asynchronous
Akata (lane 3) cells. Sizes are indicated in kilodaltons.
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nocodazole (lanes 3 to 8). Therefore, nocodazole does not
induce the viral lytic cycle. It follows that the EBNA-1 mRNA
detected in Fig. 2 is due to latent cell cycle-regulated expres-
sion from Qp, not from lytic Fp expression.
The steady-state level of EBNA-1 protein does not vary de-
tectably during the cell cycle in type I latency. To examine
EBNA-1 protein expression throughout the cell cycle, Akata
cells were again synchronized with nocodazole. From each 3-h
time point, total protein was prepared, and expression of
EBNA-1 protein was determined by Western analysis. FACS
analysis demonstrates that at 0 h following release, a majority
of the cells are in G2/M (Fig. 4A). The cells then progress into
G1, with a G1 peak at 6 h, and then into S phase, with an
S-phase peak at 15 h. Western analysis shows that there is no
detectable change in the steady-state level of EBNA-1 protein
during the cell cycle (Fig. 4B, lanes 3 to 12). The size difference
of the EBNA-1 protein in Raji compared with Akata cells is
due to the variable internal Gly-Ala repeat unit within the
EBNA-1 protein (compare lanes 2 and 3) (21).
As a control for correct cell cycle expression, E2F-1 protein
levels at each time point were analyzed by Western blotting
(Fig. 4C). In fibroblasts, E2F-1 regulates its own promoter
(22). Furthermore, its protein expression increases during G1
with a late G1/early S-phase peak. As a control for E2F-1 ex-
pression, HELs were synchronized in G0 by serum starvation.
Serum-starved HELs do not express E2F-1 (lane 1). At 18 h
following release from starvation, HELs enter late G1/early S
phase and display E2F-1 expression (lane 2). Following release
of Akata cells from nocodazole block, E2F-1 expression increases,
with an increase in G1 cells, and peaks at 9 h, which corresponds
to late G1/early S phase (lanes 4 to 7). These data demonstrate
that nocodazole treatment does not affect the proper expres-
sion of a cell cycle-regulated protein. Furthermore, the appar-
ent lack of cell cycle-dependent expression of EBNA-1 protein
is not an artifact due to nocodazole treatment.
EBNA-1 has a long half-life. The lack of any detectable
change in the expression of the EBNA-1 protein during the cell
cycle may be due to its stability. To determine the half-life of
the EBNA-1 protein, both Akata and X50-7 cells were treated
with CHX to block protein synthesis. This approach allows the
estimation of the half-life of endogenous EBNA-1 in both type
I and type III latency. Following CHX treatment, total protein
was prepared from cells at various time points, and the half-life
of the EBNA-1 protein was estimated by Western analysis
(Fig. 5, upper panel). In both Akata (type I) and X50-7 (type
III) cells, the EBNA-1 protein appears to have a half-life in
excess of 36 to 48 h. The data presented here extend those in
a previous report which indicated that EBNA-1 is stable up to
20 h (26).
As an internal control, these same lysates were examined for
the IRF-1 protein, which is reported to have a half-life of 30
min (Fig. 5, lower panel) (64). In X50-7 and Akata cells, the
IRF-1 protein has apparent half-lives of 30 min and 2 h, re-
spectively. The degradation of IRF-1 and stability of EBNA-1
demonstrate that the estimated half-life of EBNA-1 is not an
artifact of CHX treatment.
Taken together, these data show that EBNA-1 has an ex-
tended half-life. The lack of any significant degradation of
EBNA-1 up to 24 h covers the time span of the synchronization
experiment in Fig. 4. This result would explain why there is an
apparent lack of cell cycle-dependent expression of the EBNA-
1 protein. Interestingly, this same result has been obtained for
other E2F- and cell cycle-dependent genes, as discussed below.
Mutation of the E2F sites within the Q locus abolishes cell
cycle regulation of Qp activity. To determine if Qp activity is
dependent on the cell cycle, we made use of a luciferase re-
porter system which has demonstrated the cell cycle-depen-
dent transcriptional activity of other E2F-responsive promot-
ers (17, 41, 42, 55). Qp sequence from 2173 to 1115 relative
to the Qp transcriptional start site was cloned into the lucif-
erase reporter construct pGL-2 Basic (Fig. 6A, pQLUC). This
construct contains the ISRE, the Qp start site, and the entire Q
locus but lacks the Fp start site, which might obscure Qp
activity. In addition, two other reporter plasmids were con-
structed as controls. The first, pQEcoLUC, is identical in se-
quence to pQLUC, with a 3-bp mutation of the downstream
E2F site in the Q locus (QpE2Fb) to an EcoRI site (Fig. 6A).
A CAT reporter construct containing this mutation has been
shown to be repressed by EBNA-1. However, this EBNA-1-
mediated repression could not be overcome by the overexpres-
sion of E2F-1 (56). The second construct, pQ2LUC, contains
Qp sequence 2173 to 15 and lacks both E2F binding sites as
well as the two EBNA-1 binding sites of the Q locus. These
constructs were cotransfected with a b-Gal expression vector
into NIH 3T3 mouse fibroblasts, and the transfectants were
serum starved in 0.5% serum for 48 h to synchronize the cells
in G0/G1. Following starvation, the cells were released by the
addition of normal growth medium and time points were taken
FIG. 4. Level of EBNA-1 protein does not vary detectably with cell cycle in
type I latency. (A) Cell cycle status of each time point following release of Akata
cells from nocodazole block was determined by FACS analysis. (B) EBNA-1
expression was determined by Western analysis; 75-mg aliquots of total cellular
protein from each time point (lanes 4 to 12), from asynchronous akata cells (lane
3), and from DG75 cells (lane 1) and 25 mg from Raji cells (lane 2) were used.
(C) E2F-1 levels were determined by Western analysis; 50 mg of total protein
from each time point along with 150 mg of 0-h HELs (serum starved; lane 1) and
18-h HELs (late G1/early S; lane 2) were electrophoresed. Sizes in panels B and
C are indicated in kilodaltons.
FIG. 5. EBNA-1 protein has a half-life in excess of 36 to 48 h. In the upper
panel, EBNA-1 expression levels were determined by Western analysis. For
X50-7 (lanes 3 to 10) and Akata (lanes 11 to 18) cells, 25 and 100 mg of total
cellular protein, respectively, were used from each time point. For controls, 100
mg of total cellular protein for both DG75 (lane 1) and BL41 958 (lane 2) cells
were used. In the lower panel, the bottom half of the membrane used for the
EBNA-1 analysis in the upper panel was probed for IRF-1 expression by Western
analysis. Sizes are indicated in kilodaltons.
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every 6 h. From each time point, cells were sampled for FACS
analysis as well as for b-Gal and luciferase assays.
Serum starvation arrested approximately 80 to 85% of the
cells in G0/G1, as determined by FACS analysis (data not
shown). The cells entered S phase 12 h following the addi-
tion of growth medium and traversed S between 12 and 18 h
(data not shown). Concurrent with entry into and progression
through S phase, luciferase activity of pQLUC was induced an
average of 2.4-fold (Fig. 6B). Results shown summarize three
experiments. In another experiment where the cells had been
synchronized by serum starvation with 0.1% serum, 2.5-fold
activation of pQLUC was observed (data not shown). In con-
trast to pQLUC, there was no induction of luciferase activity of
pQ2LUC, which lacks both E2F sites. Additionally, there was
diminished activity of the pQEcoLUC construct, which retains
one E2F site. Both results are the average of two independent
experiments (Fig. 6B). Identical results were obtained for both
promoter constructs in an experiment where the transfec-
tants were synchronized with 0.1% serum: 1.7-fold induction of
pQEcoLUC and no induction of pQ2LUC (data not shown).
These data indicate that Qp transcriptional activity is linked to
the cell cycle through the two E2F sites which lie within the Q
locus. Furthermore, they suggest that the cell cycle-regulated
expression of EBNA-1 mRNA during type I latency is at the
level of transcription and not due to mRNA stability.
As a positive control, the E2F-responsive pHsOrc1-Luc
(21053) construct was used to demonstrate the efficiency of
the transfection and synchronization method. HsOrc1 is the
human homolog of the yeast ORC1 protein, which is involved
in DNA replication. The promoter for the HsOrc1 gene con-
tains E2F sites which link HsOrc1 expression to the cell cycle
(41). As previously reported, pHsOrc1-Luc(21053) demonstrat-
ed cell cycle activity following release from serum starvation
(41). As the cells proceeded into and through S phase, lucif-
erase activity increased approximately 7.6- and 10-fold at 18
and 24 h, respectively, validating the system (data not shown).
DISCUSSION
We have reported that a member of the E2F family activates
Qp and have predicted that Qp activity and EBNA-1 expres-
sion might therefore be cell cycle regulated (56). This report
demonstrates that expression of EBNA-1 mRNA is clearly
regulated by the cell cycle during type I latency, with mRNA
levels lowest during G1 and subsequently increasing and peak-
ing during S phase. This result suggests that Qp activity is also
cell cycle regulated, with corresponding activity during G1 and
S phases. Consistent with this hypothesis, Qp activity was in-
duced during S phase in synchronized NIH 3T3 cells. In addi-
tion, the induction of Qp was diminished by mutation of the
QpE2Fb site and abolished by deletion of both E2F binding
sites within the Q locus. Taken with our earlier report (56),
these results indicate that an E2F protein probably plays a key
role in Qp activity and are consistent with the idea that E2F
and EBNA-1 act reciprocally to regulate the promoter.
The E2F family of transcription factors includes six E2F
proteins (E2F-1, -2, -3, -4, -5, and -6) as well as two E2F-re-
lated proteins, DP-1 and DP-2, which heterodimerize with the
E2Fs (reviewed in references 2, 8, 16, 20, 34, and 62). Although
the exact function of each E2F remains unclear, it is known
that E2F-1, -2, and -3 become activated during the G1 phase of
the cell cycle upon their release from hyperphosphorylated Rb
(reviewed in references 2, 20, and 33). Availability of these
E2Fs leads to the transactivation of many genes required for
cellular DNA replication and progression of the cell cycle (12,
17, 22, 41, 42, 48, 55). It is interesting that expression of the
E2F-1 protein, which was used as a control for proper cell cycle
expression in synchronized Akata cells, occurs during G1, with
a peak in late G1 (Fig. 4), whereas the induction of EBNA-1
mRNA expression begins and the levels peak in S phase, 6 h
later (Fig. 2). This apparent discrepancy can be explained. The
induction and peak of expression of many E2F-dependent
genes occur at different points in the cell cycle (reviewed in
reference 32). For example, promoter activity and expression
FIG. 6. Qp activity is induced during S phase and is dependent on the E2F
sites within the Q locus. (A) Structure of the Qp luciferase (LUC) reporter
constructs. The bent arrow marks the Qp start site; the open square is the ISRE;
black ovals and hatched rectangles are the EBNA-1 and E2F binding sites,
respectively, within the Q locus. The upstream and downstream E2F sites are
designated QpE2Fa and QpE2Fb, respectively, in Fig. 1 and the text. The
nuleotide sequence of the QpE2Fb site (boxed sequence) in pQLUC and
pQEcoLUC is shown at the right of each reporter construct. The three mutated
base pairs within pQEcoLUC are underlined. (B) Fold induction of the Qp
luciferase reporter constructs and the vector control, pGL-2 Basic. b-Gal assays
were performed on each time point to normalize the amount of protein lysate
used in the luciferase assays. The time of S phase is shown as a black bar
spanning from 12 to 18 h after release from serum starvation.
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of both cyclin E and cyclin A are dependent on E2F (12, 17, 42,
55). However, their expression patterns differ. Cyclin E mRNA
expression is induced during G1 and peaks at the G1/S bound-
ary (13, 27). In contrast, cyclin A expression is induced at the
G1/S boundary and does not peak until late S to G2 phase,
similar to EBNA-1 mRNA levels (13, 18, 44). In another sys-
tem, the mRNA expression of both cyclins can be induced by
E2F-1 expression, although cyclin A is expressed much later
than cyclin E (12). These data demonstrate the complexities of
E2F regulation. Qp activity and EBNA-1 mRNA expression
could be regulated by any member of the E2F family. Further-
more, expression of EBNA-1 mRNA may be dependent on
E2F-1 but not necessarily mirror E2F-1 expression.
Although EBNA-1 mRNA levels clearly change, the steady-
state level of the protein does not appear to vary with cell cycle
due to the stability of EBNA-1. This is not unprecedented.
Cellular genes whose mRNA expression is cell cycle depen-
dent, but without corresponding changes in protein levels, have
been described. For example, the mRNA expression for
both subunits of ribonucleotide reductase (RR) is induced
by E2F and regulated in a cell cycle-dependent manner (7, 12,
29). In proliferating cells, both mRNAs are low in G1 and
increase during S phase. However, protein levels of the R1/M1
subunit of RR do not appear to change (29). The authors
conclude that this lack of cell cycle-dependent expression is
due to the long half-life of the R1/M1 protein (15 to 24 h) (7,
14, 29). In contrast to R1/M1, the R2/M2 subunit of RR has a
half-life of 3 h, and protein levels vary with cell cycle in pro-
liferating cells (7, 15). Similar to R1/M1, EBNA-1 is cell cycle
regulated at the mRNA level (Fig. 2) but not detectably at the
protein level (Fig. 4). The EBNA-1 protein has an extended
half-life in excess of 36 to 48 h (Fig. 5). Another possibility is
that there are small differences in EBNA-1 protein levels
which can not be distinguished by the available assay method.
As part of this study, pulse-labeling experiments to examine
EBNA-1 protein synthesis during the cell cycle were attempted
without success in synchronized Akata cells. Cells were labeled
with [35S]methionine for 3 h at the G2/M, G1, and S-phase time
points (0, 6, and 15 h, respectively). EBNA-1 was then immu-
noprecipitated with either a MAb or one of several PAbs
(generous gifts of J. Middeldorp). In contrast to type III cells,
levels of EBNA-1 protein in Akata cells are typically 20- to
50-fold lower (data not shown). The large amount of Akata
extract needed to immunoprecipitate EBNA-1 efficiently, as
detected by Western analysis, resulted in heavy 35S background
so that labeled EBNA-1 could not be distinguished.
Cell cycle regulation of EBNA-1 during type I latency may
serve several functions in episomal maintenance and viral gene
regulation. EBNA-1 functions as the origin-binding protein of
EBV and is required for replication and maintenance of the
viral episome during latency (39, 69). The episome is known to
replicate once per cell cycle, concurrently with cellular DNA
(1, 68). Therefore, cell cycle-dependent expression of EBNA-
1 mRNA may ensure that a certain level of EBNA-1 is main-
tained to populate the 24 binding sites at oriP at the time when
the episome is replicated.
The exact function of EBNA-1 at oriP is unknown. Possible
functions include the recruitment of the host DNA polymerase
during S phase or segregation of episomes to daughter cells
during mitosis (40, 43, 47, 70). The cell cycle regulation of viral
DNA replication in cycling B lymphocytes may not be medi-
ated by the level of EBNA-1 protein because EBNA-1 is pres-
ent throughout the cell cycle (Fig. 4). Regulation of replication
by EBNA-1 must be at some other level. For example, EBNA-
1 may interact with a component of the cellular DNA replica-
tion machinery in a cell cycle-dependent manner. A recent
report has shown the interaction of EBNA-1 with RPA, the
single-strand DNA-binding protein (70). Additionally, EBNA-
1 may bind to oriP at precise times during the cell cycle.
Interestingly, none of the sequences in the spaces between the
24 EBNA-1 binding sites in oriP contain E2F sites or bind
E2F-1 in vitro (56). Although not detected in Fig. 4, cell cycle-
dependent phosphorylation of EBNA-1 may regulate either of
these or other unknown functions of EBNA-1.
A recent report claims that Qp is not cell cycle regulated
(51). This conclusion was reached by methods similar to those
used in this study but did not reveal variation in luciferase ac-
tivity with cell cycle. However, Schaefer et al. (51) chose a
construct which contains 1,730 nucleotides of sequence up-
stream of Qp which includes the Fp transcriptional start site
plus sequence of unknown function. It has been demonstrated
that Fp and Qp reporter constructs have multiple sites of tran-
scriptional initiation (35). Therefore, it is not clear that Qp is
the site of transcriptional initiation in this construct when trans-
fected into NIH 3T3 cells. For the luciferase experiments pre-
sented in this report, Qp promoter sequences were cloned such
that Fp and other extraneous viral sequences which might ob-
scure Qp activity were not included. This construct, pQLUC,
demonstrated a 2.4-fold induction in luciferase activity coinci-
dent with the progression of the synchronized NIH 3T3 cells
through S phase. Interestingly, this is the same level of induc-
tion observed for the cyclin E promoter, which is also E2F re-
sponsive (17).
Schaefer et al. proposed a model for the alleviation of
EBNA-1 repression and activation of Qp whereby an HMG-
I(Y)-containing complex might bind directly downstream of
the ISRE and overlap the transcriptional start site (51). This
complex would also overlap the 59 end of the upstream EBNA-
1 binding site in the Q locus. Therefore, the putative HMG-
I(Y)-containing complex could displace or inhibit the binding
of EBNA-1 to the 59 site of the Q locus. However, this model
leaves important questions unanswered. First, it does not suf-
ficiently explain how EBNA-1 is dislocated from the 39 EBNA-
1 binding site in the Q locus. Second, and more importantly,
precise mutation of the sequences supposedly bound by HMG-
I(Y) in vitro have absolutely no effect on promoter activity (36).
Other data support the idea that the E2F sites in Qp are re-
quired for full promoter activity (36). Nonkwelo et al. showed
that in proliferating lymphocytes, mutation of the core se-
quences of either E2F-binding element (Fig. 1C, QpE2Fa and
QpE2Fb) reduced promoter activity by 50 to 70% in the ab-
sence of EBNA-1 (36). These data raise the possibility that
QpE2Fa and QpE2Fb have different roles in cycling versus
noncycling cells (Fig. 7). In cycling B lymphocytes, E2F would
overcome EBNA-1 repression and activate Qp as the cells
enter S phase, similar to other E2F-responsive promoters (Fig.
7A). In resting, G0 B lymphocytes, E2F-responsive promoters
are repressed by a complex of E2F (i.e., E2F-4 or -5) and a
member of the pocket protein family (i.e., p107 or p130) (re-
viewed in references 2, 20, 33, and 34). Therefore, these sites
in Qp may be required for repression of Qp during G0. Inter-
estingly, QpE2Fa and QpE2Fb resemble the E2F sites in the
cyclin A, B-myb, and cdc2 promoters (Fig. 1C) (6, 28, 55). In
particular, none of these E2F elements has the characteristic
thymidine residues flanking the 59 end of the consensus
sequence (reviewed in references 2 and 33). Additionally,
QpE2Fb matches the B-myb E2F site over seven consecutive
base pairs. Furthermore, the E2F sites in both the B-myb and
cdc2 promoters appear to be important for repression, as both
are occupied during G0 (61, 72). As cells move through G1,
these sites are vacated, and expression of both genes is in-
duced. Taken together with the data of Nonkwelo et al. (36)
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and Sung et al. (56), the data presented in this study suggest
that the E2F sites in Qp could be important for the repression
of Qp in a nonproliferating, G0 cell (Fig. 7B). This may be the
situation in type 0 latency.
Synthesis of EBNA-1 dependent on the cell cycle may be
pertinent in the normal carrier state for EBV in the human
host. Others have reported that in the immunocompetent host,
EBV episomes reside in a population of small resting G0 B
lymphocytes that express little or no EBNA-1 message as de-
tected by reverse transcription-PCR (9, 30, 31, 60). Taken to-
gether, these data suggest that in the normal carrier state, EBV
episomes exist in nonproliferating B lymphocytes that do
not express EBNA-1 message, termed type 0 latency. While
EBNA-1 mRNA is not transcribed, detection of EBNA-1 pro-
tein is not possible in these cells. However, due to the protein’s
stability, preexisting subdetectable amounts of EBNA-1 pro-
tein that bind to the Q locus might be present. In these G0
cells, E2F would be transcriptionally inactive, and Qp would
also be inactive due to EBNA-1 protein bound at the Q locus
(Fig. 7B, model i). As these cells begin to proliferate due to
some physiological stimulus, E2F would become active, bind to
the Q locus, compete with or displace EBNA-1, and activate
Qp. Alternatively, Qp may be inactive in G0 due to a repressive
E2F complex bound to the Q locus (Fig. 7B, model ii). As in
the first model, when the cells enter the cell cycle, p130 would
be hyperphosphorylated, and E2F either would become tran-
scriptionally active or would dissociate from the Q locus, sim-
ilar to the B-myb and cdc2 promoters, leading to activation of
Qp. In either model, EBNA-1 expression is tied to prolifera-
tion of the latently infected cell, the cell cycle, and DNA
replication. This linkage would ensure that EBNA-1 expres-
sion occurs concurrently with cellular and episomal replication
so that oriP can be populated by EBNA-1 and the episome can
be maintained.
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